
    
      60 patients of esophageal cancer with TNM stage of tumor stage II-III,who had received
      surgery and kept their tumor tissue, will be randomly divided into group A (receive cancer
      tissue antigen sensitized D-CIK immune cells in combination with chemotherapy treatment) or
      group B (just receive chemotherapy), and the randomize ratio will be 1:1. Patients in group A
      will receive 3 cycles of autologous antigen-sensitized DC-CIK cells treatment (every 4 weeks)
      and chemotherapy. Patients in group B will receive only 3 cycles chemotherapy.
    
  